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ABSTRACT
Introduction: Fractional exhaled nitric oxide
(FeNO) is a valuable tool for measuring allergic
airway inflammation in children with asthma,
particularly in those for whom other tests are
difficult to perform. The use of a 6-s exhalation
time (6-s mode) rather than 10 s (10-s mode)
used for adults is in line with current
recommendations, making FeNO a feasible
option for younger children. However, sparse
data are available that demonstrate the
agreement between exhalation modes in
young children.
Methods: This study assessed the degree of
agreement of FeNO measured using the 6- and
10-s modes in young children (6–10 years) with
asthma and the feasibility of use in younger
children (4–5 years) with asthma using the
NIOX VERO analyzer. Enrolment was
stratified so that 15 subjects had
FeNO[35 ppb and 35 had FeNO\35 ppb.
Results: For subjects aged 6–10 years,
agreement and repeatability was shown with
mean observed FeNO measurements of
34.36 ppb (6-s mode) and 33.35 ppb (10-s
mode) and paired differences were centered
close to 0 (median 0.50). In the 4–5-year age
group, ten subjects had a valid 6-s mode FeNO
result (mean value, 12.6 ppb) of which seven
(70%) also had a valid 10-s mode FeNO result
(mean value, 10.6 ppb) with good
correspondence in FeNO results between the
modes.
Conclusions: Children aged 4–10 years can
successfully perform FeNO measurements
using the NIOX VERO analyzer in the 6-s or
the 10-s modes. FeNO measurements were
repeatable and consistent with a high degree
of agreement between the two modes in
children aged 6–10 years. Younger children
(4–5 years) also successfully performed FeNO
measurements using both modes and were
more successful using the 6-s mode. Thus, in
young children, successful FeNO measurements
can be obtained, providing physicians with
important information in this age group to aid
in the diagnosis and treatment of asthma.
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INTRODUCTION
Fractional exhaled nitric oxide (FeNO) is a
valuable tool for measuring allergic airway
inflammation in patients with asthma. It is a
direct marker of T-helper type 2 (Th2)-driven
inflammation in the airways and can assist in
the diagnosis of asthma [1], help identify
patients who will respond to inhaled
corticosteroids (ICS) [2], and predict risk of
asthma worsening [3]. When used to regularly
monitor patients, FeNO has been shown to
reduce exacerbations of both in adults [4, 5] and
in pediatric patients [6, 7]. FeNO may also
predict the development of persistent asthma,
so methods to measure FeNO in younger
patients is important [8–11].
Measuring FeNO is particularly valuable in
young children for whom other tests are
difficult to perform. Obtaining reliable
spirometry measurements can be difficult, and
neither this nor other routinely available tests,
such as the Childhood Asthma Control Test
(C-ACT), provide information about airway
inflammation [1]. In contrast, FeNO
measurements are easy, quick to perform in
the clinic, and reproducible [8–10]. In addition,
FeNO testing uses a different respiratory
maneuver to the other assessments, which
does not involve a forced vital capacity
maneuver. This makes it easier for children,
and especially young children, to perform,
therefore aiding cooperation [11].
However, the use of FeNO in children has its
own challenges [11]. Children are sometimes
unable to exhale for 10 s to meet the
recommended time for a measurement as
approved by the FDA, and this can make
monitoring children difficult.
NIOX VERO (Fig. 1) has been recently
approved as the next-generation FeNO
analyzer to NIOX MINO and is now available
for clinical use in the European Union (EU),
United States of America (USA), Japan, China,
and other major markets. Patients aged 7 years
and older can use NIOX VERO and the device
may be suitable for some children aged from
4 years providing they are able to cooperate
with the procedure. NIOX VERO may help to
overcome the challenges faced when measuring
FeNO in younger children because it enables
physicians to use an exhalation time of either
10 s (10-s mode) or 6 s (6-s mode) once the latter
is approved by the FDA (note: NIOX VERO 6-s
mode is available in the EU).
Current guidelines require exhalation of at
least 4 s for children younger than 12 years;
longer than 6 s is acceptable for children over 12
years of age [12]. The use of the 6-s mode to
measure FeNO in children rather than the 10-s
mode used for adults is in line with these
recommendations and makes FeNO a feasible
option for younger children.
Sparse data are available that demonstrate
the agreement (or comparability) between the
6-s and 10-s modes for the measurement of
FeNO in children aged 6–10 years. The NIOX
VERO has the capability of measuring FeNO
using both the 6-s and 10-s modes. This study
assessed the degree of agreement of FeNO
measured using the 6-s and 10-s modes in
young children (6–10 years) and assessed the




This was a randomized, single-visit,
point-of-care, clinical validation study
conducted at a single study center in the USA
on October 12, 2013. The study was approved
by the local Institutional Review Board (IRB;
Fig. 1 An illustration of the NIOX Vero analyzer
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Sterling IRB, Atlanta, GA, USA) and was
conducted in compliance with Good Clinical
Practice and the Declaration of Helsinki.
Subjects
Males and females aged 4–10 years were
enrolled who had physician—diagnosed
asthma and whose primary language was
English. In the 4–5 years age group, ten
subjects were planned; in the 6–10 years age
group, enrolment was planned such that
15 subjects were to have FeNO above 35 ppb
and 35 subjects were to have FeNO below
35 ppb. Excluded subjects had any other
pulmonary disease, acute asthma symptoms,
respiratory illness or sinusitis; had not refrained
from taking food or drink (other than water)
within 15 min before the FeNO measurement,
or had done strenuous exercise within 1 h of the
FeNO assessment. Informed consent was
obtained from each subject’s legally authorized
representative before being included in the
study.
Device and Training
After enrolment, an operator demonstrated the
use of the NIOX VERO device to each subject.
Under the direction of an operator, each subject
was allowed up to ten attempts to perform a
single valid FeNO measurement with a rest
break of 30 s or less between measurements. A
measurement was considered valid if the FeNO
value was displayed on the device. If after
ten attempts the subject was unable to
perform a valid measurement, the subject was
discharged from the study. To avoid bias,
subjects were randomized to
two measurements taken using the 6-s mode
followed by two measurements using the 10-s
mode or vice versa.
Subjects aged 4 and 5 years were not
randomized and were included in the study to
assess their ability to successfully complete
FeNO measurements as evidenced by display
of a FeNO value on the NIOX VERO device
using both the 6-s and 10-s modes. Subjects in
this age group performed one FeNO
measurement using the 6-s mode and
following successful completion of this, they
attempted to perform a measurement using the
10-s mode.
Assessments
NIOX VERO was used according to the
appropriate user manual [13]. In brief, each
subject was instructed to breathe out fully to
empty their lungs, close their lips around the
mouthpiece on the filter to prevent air leakage,
and then inhale deeply to total lung capacity. A
graphic (in the shape of a cloud) on the device’s
screen moves as the subject inhales. Each
subject then exhaled slowly through the filter
while keeping the cloud within the limits
shown by the white lines on the screen.
Subjects exhaled until the cloud moved past
the flag shown on the right-hand side of the
screen. Occurrences of adverse events (AE) or
serious injuries were monitored. A worsening of
asthma was not considered an AE unless this
event met the criteria for serious injury.
Statistical Methods
The primary objectivewas to assess the estimated
bias at the 35 ppb cut-off usingweightedDeming
regression analysis, whichmodeled the observed
6-smode FeNOmeasurement as a function of the
10-s mode FeNO measurement. The mean value
of the replicate FeNO measurements for each
mode was used for the analyses. Values of FeNO
recorded as ‘‘below 5 ppb’’ were considered to
have a value of ‘‘5 ppb’’. Observed FeNO
measurements collected using the 6-s mode
were graphically compared to the
corresponding FeNO collected using the 10-s
mode.
Agreement was assessed using a weighted
Deming regression analysis of observed data
and Bland–Altman plots [14]; Bland–Altman
graphs plotted the paired difference (6-s
mode - 10-s mode) against the mean FeNO
results for the average 6-s and average 10-s
modes to compare the difference of test results
between the methods. The acceptable bias at the
35 ppb cut-off value was pre-specified to be 7%.
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Average bias was assessed based on the
weighted Deming regression across the entire
range of observed FeNO test values. FeNO values
measured using the 10-s mode were compared
with those measured using the 6-s mode to
evaluate the percentage of subjects within the
tolerance limits.
A sample size of 50 subjects aged 6–10 years
was chosen based on the NCCLS EP9-A2
guidance document [15], which recommends a
sample size of at least 40 subjects. For this study,
the number was increased to 50 to allow for
missing data or invalid results (up to 20%). All
statistical analyses were performed using SAS
Software, release V9.2 (SAS Institute, Cary, NC,
USA).
Data Availability The datasets generated
during and/or analyzed during the current
study are not publicly available due the fact
that it did not fall under the FDAAA 2007
requirements to publicly disclose the data, but
data are available from the corresponding
author on reasonable request.
RESULTS
Subjects
Overall, 65 subjects (53 subjects aged 6–10 years
and 12 subjects aged 4–5 years) were enrolled
and completed the study (Table 1).
Three subjects (two subjects aged 4–5 years and
one subject aged 6–10 years) did not have valid
FeNO assessments within ten attempts;
48 (90.6%) aged 6–10 years had at least one
evaluable FeNO measurement in both the 6-s
and 10-s modes and were considered the
Evaluable Population; 45 (84.9%) aged
6–10 years had two valid observations during
both the 6-s and 10-s modes. In the 6–10 years
age group, the mean number of attempts at
performing the FeNO measurement was 6.17
Table 1 Demographics for all subjects and for those in the sub-groups aged 6–10 years and 4–5 years
Age group (years) Total
4–5 6–10
Number of subjects 12 53 65
Mean age (standard deviation), years 4.4 (0.51) 8.1 (1.35) 7.4 (1.89)
Minimum, maximum 4, 5 6, 10 4, 10
Sex, n (%), male 7 (58.3) 38 (71.7) 45 (69.2)
Ethnicity, n (%)
Hispanic or Latino 4 (33.3) 11 (20.8) 15 (23.1)
Not Hispanic or Latino 7 (58.3) 42 (79.2) 49 (75.4)
Not reported 1 (8.3) 0 1 (1.5)
Race, n (%)
American Indian 0 1 (1.9) 1 (1.5)
Asian 0 2 (3.8) 2 (3.1)
Black or African American 2 (16.7) 6 (11.3) 8 (12.3)
White 9 (75.0) 43 (81.1) 52 (80.0)
Other 1 (8.3) 1 (1.9) 2 (3.1)
Mean height, cm (standard deviation) 112.0 (5.97) 131.5 (10.16) 127.9 (12.12)
Minimum, maximum 103, 122 110, 155 103, 155
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(range, 4–10), In the 4–5 years age group, the
mean number of attempts at performing the
FeNO measurement was 7.92 (range, 2–10).
No AEs or serious injuries were reported.
6–10-Year-Olds
Agreement Between Exhalation Modes
Randomization sequences of the assessments or
replicate order did not show a significant
influence on the measurement. The mean
observed FeNO measurements were similar
across the randomization sequence and
replicate for both modes with overall means of
34.36 ppb (6-s mode) and 33.35 ppb (10-s
mode) (Table 2). The 10-s to 6-s randomization
sequence group had means that were slightly
larger on every comparison; however, the
medians for both modes were similar in both
randomization sequences (Supplementary
Table 1). The difference occurred because two
subjects had observed FeNO results above
100 ppb and both appeared in the 10-s to 6-s
sequence.
No outliers were identified in relation to
observed FeNO results when investigated as a
within-method or between-method outlier [15].
Paired differences in average FeNO results ranged
from -11.0 to 13.0 ppb and were centered close
to 0 (mean 1.01 ± 4.59; median 0.50).
Weighted Deming regression analysis
showed no evidence of systematic bias in
measurements between the 6-s and 10-s modes
because the estimated intercept was
-0.564 ppb, which is not significantly
different from 0 (p = 0.3642) (Fig. 2), and the
estimated slope was 1.057 and not significantly
different from 1 (p = 0.0912).
Average bias of the 6-s mode predicted from
the 10-s mode, expressed as a percentage of the
10-s mode, was low (2.7%) across the full range
of observed FeNO results (6.0–129.0 ppb). The
absolute estimated bias at the 35 ppb cut-off
value (1.43) was significantly below the
pre-specified limit of 7 (p\0.0001). The
95% CI around the bias contained 0 (-0.18 to
03.05) indicating no bias. The upper bound of
the CI on the estimated bias at 35 ppb was 8.7%
of the cut-off value, suggesting bias well below
the pre-specified cut-off of 20%.
An even spread of paired differences in
average FeNO results was seen between the
exhalation modes with larger differences only
noted for two subjects with the largest observed
FeNO results (Fig. 3). Data points tended to be
scattered above the reference line than below
and, overall, the plot showed no evidence of
any systematic bias between the exhalation
modes.
Repeatability
When using either the 6-s or 10-s modes, the
FeNO measurements were repeatable. The mean
intra-subject standard deviation was slightly
higher for the 10-s mode compared to that of
the 6-s mode (1.776 versus 1.414), but the
median values were the same (0.707). Our data
provided evidence that there was a similar
degree of repeatability within the 6-s and 10-s
modes given that the median paired difference
was 0 and there was no statistically significant
difference noted (p = 0.3090).
Table 2 Observed average fractional exhaled nitric oxide (FeNO) results by exhalation mode and the paired intra-subject
differences (6 s–10 s) in average FeNO between modes (evaluation population)
Exhalation mode Paired difference
(6 s2 10 s)6 s 10 s
Number of subjects who successfully
completed C1 measurement
48 48 48
Mean FeNO (ppb) 34.36 (25.202) 33.35 (24.507) 1.01 (4.587)
Median FeNO (ppb) 28.00 31.25 0.50
Minimum, maximum 5.5, 114.5 6.5, 120.0 -11.0, 13.0
FeNO fractional exhaled nitric oxide
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Assessment of Tolerance Limits
FeNO values were within the tolerance limits for
a high proportion of subjects (45/48; 93.8%)
with an exact 95% CI of 82.8–98.7% (Table 3).
Subjects were considered to be within the
tolerance limit if they had an absolute
difference (average 6 s FeNO – average 10 s
FeNO) below 10 ppb for subjects with a 10-s
mode FeNO value below 35 ppb, or an absolute
difference below 20% if their 10-s mode FeNO
value was 35 ppb or more. Twenty-nine subjects
had a reference FeNO below 35 ppb, all were
within tolerance limits and the maximum
absolute difference was 8.5 ppb. Nineteen had
Fig. 2 Weighted Deming regression analysis plot of observed fractional exhaled nitric oxide (FeNO) results for each of the
replicate pairs, showing agreement between the FeNO measurements from the 6-s exhalation mode with those obtained
using the 10-s exhalation mode for subjects aged 6–10 years (evaluation population)
Fig. 3 Bland–Altman plot showing the paired differences in average fractional exhaled nitric oxide results between the 6-s
exhalation mode and 10-s exhalation mode in subjects aged 6–10 years (evaluation population for subjects with two
observations on both modes)
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a reference FeNO of 35 ppb or more of which
16 (84.2%) were within tolerance limits and the
absolute percent differences for the three
outside the tolerance limits were close to the
limit: 21.1, 21.7, and 30.0%.
Younger sub-group (4–5-year-olds)
Ten (83%) subjects had a valid 6-s mode FeNO
result with a mean value of 12.6 ppb, of which
seven (70%) also had a valid 10-s mode FeNO
result with a mean value of 10.6 ppb (Table 4).
For these seven subjects, there was good
correspondence in FeNO results between the
6 s- and 10-s modes (Fig. 4).
DISCUSSION
There was good correlation in FeNO values
between the 6-s and 10-s modes for the selected
age groups and the measurement of FeNO using
NIOX VERO was safe with no AEs or serious
injuries reported during the study.
Our results support the agreement and
repeatability of the NIOX VERO device using
both exhalation modes in children aged
6–10 years. These data support the viability of
the 6-s mode as an alternative option for
assessing FeNO in children who are unable to
perform the 10-s assessment.
There was a high success rate overall, and
particularly with the 6-s mode in the 4- and
5-year-olds. While the study was not powered to
examine the correlation of both test modes in
this sub-group, we were able to plot the
correlation and show good agreement in the
limited number of observations available and
agreed with the findings from the overall study
population.
Therefore, successful FeNO measurements
can be made in young children aged
4–10 years, enabling physicians to obtain
important information to help in the
diagnosis and treatment of asthma in this age
group. The similarity of observed results
Table 3 Assessment of tolerance limits given as absolute percent difference [(6 s–10 s)/10 s] in average fractional exhaled
nitric oxide (evaluation population)
N5 48
Subjects with reference FeNO\35 ppb
n 29
Absolute % difference [(6 s–10 s)/10 s] in average FeNO
Mean (SD) 1.78 (1.766)
Median 1.50
Min, max 0.0, 8.5
Subjects within tolerance limits (95% exact CI) 29/29 (100.0%) (88.1%, 100.0%)
Subjects with reference FeNO C 35 ppb
n 19
Absolute percent difference [(6 s–10 s)/10 s] in average FeNO
Mean (SD) 10.10 (7.902)
Median 9.17
Min, max 0.0, 30.0
Subjects within tolerance limits (95% exact CI) 16/19 (84.2%) (60.4%, 96.6%)
Overall subjects within tolerance limits (95% exact CI) 45/48 (93.8%) (82.8%, 98.7%)
CI conﬁdence interval, FeNO fractional exhaled nitric oxide
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between the modes, the low bias and
intra-subject standard deviation, and the high
percentage of subjects within the tolerance
limits provide evidence of a high degree of
agreement between the modes and support the
viability of the 6-s mode as an alternative
option in assessing FeNO.
Previous studies have shown a correlation
between the 6-s and 10-s modes using NIOX
MINO in children aged 4–17 years [16–18] for
which two studies showed a greater success rate
when the 6-s mode was used in younger
children [16, 18]. Other studies have also
shown the feasibility of the 6-s mode in
Table 4 Fractional exhaled nitric oxide results for subjects aged 4–5 years by exhalation time mode (safety population for
subjects aged 4–5 years)
N5 12
FeNO 6-s mode
Number who successfully completed at least one measurement, n (%) 10 (83.3)
Mean FeNO (standard deviation), ppb 12.6 (13.28)
Median FeNO, ppb 9.0
Minimum, maximum, ppb 5, 49
FeNO 10-s mode
Number who successfully completed at least one measurement, n (%) 7 (58.3)
Mean FeNO (standard deviation), ppb 10.6 (4.86)
Median FeNO, ppb 10.0
Minimum, maximum 5,19
FeNO fractional exhaled nitric oxide
Fig. 4 Weighted Deming regression analysis of observed fractional exhaled nitric oxide (FeNO) results from the seven
subjects, aged 4 and 5 years, with valid FeNO measurements in both the 6-s and 10-s exhalation modes (safety population
for subjects aged 4–5 years)
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children (aged 4–18 years) using the NIOX
MINO device [19–23].
This was a one-visit study simply designed in
order to evaluate clinical validation of the NIOX
VERO device using the 6-s and 10-s modes in
young children. Study design limitations
included the small sample size, though it was
adequate to show a strong correlation, and the
fact that measurements were taken at one visit,
and all subjects were clinically stable.
Furthermore, this was a single-center study.
Therefore, since FeNO performance quality
depends on instruction and training, the data
reported here may apply to an experienced
team with trained personnel, but not
necessarily to broader primary or secondary
care settings. The fact that all measurements
were done on the same device with the same
patient on the same day is considered a strength
since it gave a consistent test of the two
exhalation modes.
CONCLUSIONS
We have shown that children aged 6–10 years
are able to successfully perform FeNO
measurements using the 6-s or 10-s exhalation
modes using the NIOX VERO analyzer. FeNO
measurements were repeatable and consistent
and with a high degree of agreement between
the two modes. Younger children aged 4 and
5 years also successfully performed FeNO
measurements using both modes with more
success seen using the 6-s mode. Performing
FeNO measurements using the shorter
exhalation time provides an alternative and
feasible option in children who are unable to
perform the 10-s measurement. Therefore,
successful FeNO measurements can be
obtained in young children using the NIOX
VERO analyzer and provides physicians with
important information to aid in the diagnosis
and treatment of asthma in this age group.
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